Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

Inclusion Criteria: * Male and females ≥ 18 years of age * ECOG performance status ≤ 1 * Pathologically or histologically confirmed advanced non-small cell lung cancer (unresectable Stage IIIb or IV) that has progressed after treatment with at least one chemotherapy regimen; measurable disease is not required for enrollment into this trial * All Adverse Events of any prior chemotherapy, surgery, or radiotherapy, must have resolved to Grade ≤ 2 * Signed informed consent Exclusion Criteria: * Administration of certain chemotherapy, biological, immunotherapy, radiation therapy, surgery or investigational agent within specified time frames * Significant cardiac history * Prior treatment with tumor vascular disruptive agents * Seizure disorder * Brain metastases * Active uncontrolled bacterial, viral, or fungal infection, requiring systemic therapy * Known infection with human immunodeficiency virus (HIV), or active hepatitis A, B, or C * Patients with a prior hypersensitivity reaction to product components * Pregnant or breast-feeding women. * Concurrent, active second malignancy for which the patient is receiving therapy, excluding basal cell carcinoma of the skin or carcinoma in situ of the cervix * Unwilling or unable to comply with procedures required in this protocol